Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Infratil's 48.1% investment in CDC is now valued at between A$2,972.8 million to A$3,551.1 million (with a midpoint of A$3,239.2 million).
This valuation increase reflects the benefit of CDC's recent refinancing and expansion of its debt facilities, the inclusion of two additional New Zealand developments, and changes to the blended discount rate used for the valuation.
These were partially offset by updates to macro-economic assumptions, principally around future levels of inflation in Australia and New Zealand.